Cargando…
Integrative pharmacogenomics revealed three subtypes with different immune landscapes and specific therapeutic responses in lung adenocarcinoma
BACKGROUND: Pharmacogenomics is crucial for individualized drug therapy and plays an increasingly vital role in precision medicine decision-making. However, pharmacogenomics-based molecular subtypes and their potential clinical significance remain primarily unexplored in lung adenocarcinoma (LUAD)....
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Research Network of Computational and Structural Biotechnology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271977/ https://www.ncbi.nlm.nih.gov/pubmed/35832634 http://dx.doi.org/10.1016/j.csbj.2022.06.064 |
_version_ | 1784744794034012160 |
---|---|
author | Ge, Xiaoyong Liu, Zaoqu Weng, Siyuan Xu, Hui Zhang, Yuyuan Liu, Long Dang, Qin Guo, Chunguang Beatson, Richard Deng, Jinhai Han, Xinwei |
author_facet | Ge, Xiaoyong Liu, Zaoqu Weng, Siyuan Xu, Hui Zhang, Yuyuan Liu, Long Dang, Qin Guo, Chunguang Beatson, Richard Deng, Jinhai Han, Xinwei |
author_sort | Ge, Xiaoyong |
collection | PubMed |
description | BACKGROUND: Pharmacogenomics is crucial for individualized drug therapy and plays an increasingly vital role in precision medicine decision-making. However, pharmacogenomics-based molecular subtypes and their potential clinical significance remain primarily unexplored in lung adenocarcinoma (LUAD). METHODS: A total of 2065 samples were recruited from eight independent cohorts. Pharmacogenomics data were generated from the profiling of relative inhibition simultaneously in mixtures (PRISM) and the genomics of drug sensitivity in cancer (GDSC) databases. Multiple bioinformatics approaches were performed to identify pharmacogenomics-based subtypes and find subtype-specific properties. RESULTS: Three reproducible molecular subtypes were found, which were independent prognostic factors and highly associated with stage, survival status, and accepted molecular subtypes. Pharmacogenomics-based subtypes had distinct molecular characteristics: S-Ⅰ was inflammatory, proliferative, and immune-evasion; S-Ⅱ was proliferative and genetics-driven; S-III was metabolic and methylation-driven. Finally, our study provided subtype-guided personalized treatment strategies: Immune checkpoint blockers (ICBs), doxorubicin, tipifarnib, AZ628, and AZD6244 were for S-Ⅰ; Cisplatin, camptothecin, roscovitine, and A.443654 were for S-Ⅱ; Docetaxel, paclitaxel, vinorelbine, and BIBW2992 were for S-III. CONCLUSION: We provided a novel molecular classification strategy and revealed three pharmacogenomics-based subtypes for LUAD patients, which uncovered potential subtype-related and patient-specific therapeutic strategies. |
format | Online Article Text |
id | pubmed-9271977 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Research Network of Computational and Structural Biotechnology |
record_format | MEDLINE/PubMed |
spelling | pubmed-92719772022-07-12 Integrative pharmacogenomics revealed three subtypes with different immune landscapes and specific therapeutic responses in lung adenocarcinoma Ge, Xiaoyong Liu, Zaoqu Weng, Siyuan Xu, Hui Zhang, Yuyuan Liu, Long Dang, Qin Guo, Chunguang Beatson, Richard Deng, Jinhai Han, Xinwei Comput Struct Biotechnol J Research Article BACKGROUND: Pharmacogenomics is crucial for individualized drug therapy and plays an increasingly vital role in precision medicine decision-making. However, pharmacogenomics-based molecular subtypes and their potential clinical significance remain primarily unexplored in lung adenocarcinoma (LUAD). METHODS: A total of 2065 samples were recruited from eight independent cohorts. Pharmacogenomics data were generated from the profiling of relative inhibition simultaneously in mixtures (PRISM) and the genomics of drug sensitivity in cancer (GDSC) databases. Multiple bioinformatics approaches were performed to identify pharmacogenomics-based subtypes and find subtype-specific properties. RESULTS: Three reproducible molecular subtypes were found, which were independent prognostic factors and highly associated with stage, survival status, and accepted molecular subtypes. Pharmacogenomics-based subtypes had distinct molecular characteristics: S-Ⅰ was inflammatory, proliferative, and immune-evasion; S-Ⅱ was proliferative and genetics-driven; S-III was metabolic and methylation-driven. Finally, our study provided subtype-guided personalized treatment strategies: Immune checkpoint blockers (ICBs), doxorubicin, tipifarnib, AZ628, and AZD6244 were for S-Ⅰ; Cisplatin, camptothecin, roscovitine, and A.443654 were for S-Ⅱ; Docetaxel, paclitaxel, vinorelbine, and BIBW2992 were for S-III. CONCLUSION: We provided a novel molecular classification strategy and revealed three pharmacogenomics-based subtypes for LUAD patients, which uncovered potential subtype-related and patient-specific therapeutic strategies. Research Network of Computational and Structural Biotechnology 2022-07-02 /pmc/articles/PMC9271977/ /pubmed/35832634 http://dx.doi.org/10.1016/j.csbj.2022.06.064 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research Article Ge, Xiaoyong Liu, Zaoqu Weng, Siyuan Xu, Hui Zhang, Yuyuan Liu, Long Dang, Qin Guo, Chunguang Beatson, Richard Deng, Jinhai Han, Xinwei Integrative pharmacogenomics revealed three subtypes with different immune landscapes and specific therapeutic responses in lung adenocarcinoma |
title | Integrative pharmacogenomics revealed three subtypes with different immune landscapes and specific therapeutic responses in lung adenocarcinoma |
title_full | Integrative pharmacogenomics revealed three subtypes with different immune landscapes and specific therapeutic responses in lung adenocarcinoma |
title_fullStr | Integrative pharmacogenomics revealed three subtypes with different immune landscapes and specific therapeutic responses in lung adenocarcinoma |
title_full_unstemmed | Integrative pharmacogenomics revealed three subtypes with different immune landscapes and specific therapeutic responses in lung adenocarcinoma |
title_short | Integrative pharmacogenomics revealed three subtypes with different immune landscapes and specific therapeutic responses in lung adenocarcinoma |
title_sort | integrative pharmacogenomics revealed three subtypes with different immune landscapes and specific therapeutic responses in lung adenocarcinoma |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271977/ https://www.ncbi.nlm.nih.gov/pubmed/35832634 http://dx.doi.org/10.1016/j.csbj.2022.06.064 |
work_keys_str_mv | AT gexiaoyong integrativepharmacogenomicsrevealedthreesubtypeswithdifferentimmunelandscapesandspecifictherapeuticresponsesinlungadenocarcinoma AT liuzaoqu integrativepharmacogenomicsrevealedthreesubtypeswithdifferentimmunelandscapesandspecifictherapeuticresponsesinlungadenocarcinoma AT wengsiyuan integrativepharmacogenomicsrevealedthreesubtypeswithdifferentimmunelandscapesandspecifictherapeuticresponsesinlungadenocarcinoma AT xuhui integrativepharmacogenomicsrevealedthreesubtypeswithdifferentimmunelandscapesandspecifictherapeuticresponsesinlungadenocarcinoma AT zhangyuyuan integrativepharmacogenomicsrevealedthreesubtypeswithdifferentimmunelandscapesandspecifictherapeuticresponsesinlungadenocarcinoma AT liulong integrativepharmacogenomicsrevealedthreesubtypeswithdifferentimmunelandscapesandspecifictherapeuticresponsesinlungadenocarcinoma AT dangqin integrativepharmacogenomicsrevealedthreesubtypeswithdifferentimmunelandscapesandspecifictherapeuticresponsesinlungadenocarcinoma AT guochunguang integrativepharmacogenomicsrevealedthreesubtypeswithdifferentimmunelandscapesandspecifictherapeuticresponsesinlungadenocarcinoma AT beatsonrichard integrativepharmacogenomicsrevealedthreesubtypeswithdifferentimmunelandscapesandspecifictherapeuticresponsesinlungadenocarcinoma AT dengjinhai integrativepharmacogenomicsrevealedthreesubtypeswithdifferentimmunelandscapesandspecifictherapeuticresponsesinlungadenocarcinoma AT hanxinwei integrativepharmacogenomicsrevealedthreesubtypeswithdifferentimmunelandscapesandspecifictherapeuticresponsesinlungadenocarcinoma |